Commercialization of Cardiovascular Treatment

At Janssen, our worldwide commercial entities are working to market and ensure access to medicines in more than 175 countries. We have success rates in securing approvals, trademarks and access which are well above the industry average. We are able to draw upon the significant experience of teams and colleagues at Janssen to ensure our late-stage development process can deliver the medicines to patients that need them most. As part of the Janssen Pharmaceutical Companies of Johnson & Johnson, we are united by the vision of the most broadly-based healthcare company in the world, while remaining flexible enough to focus on the specific unmet medical needs in each market and geography we serve.

We believe that medicines that pioneer new targets—such as one that works on the kidney, a new target for type 2 diabetes, and another that inhibits Factor Xa in the coagulation cascade—can potentially offer transformational options and care for patients. You can view our full list of products here.